Effects of synthetic cannabinoids on psychomotor, sensory and cognitive functions relevant for safe driving

Vasco Orazietti1, Giuseppe Basile2, Raffaele Giorgetti3 and Arianna Giorgetti1,*

1Department of Excellence of Biomedical Sciences and Public Health, Marche Polytechnic University of Ancona, Ancona, Italy, 2Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Galeazzi Orthopedics Institute, Milan, Italy, 3Unit of Legal Medicine, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy

Recreational use of Synthetic Cannabinoids (SCs), one of the largest groups of New Psychoactive Substances (NPS), has increased globally over the past few years. Driving is a structured process requiring the cooperation of several cognitive and psychomotor functions, organized in different levels of complexity. Each of these functions can be affected when Driving Under the Influence (DUI) of SCs. In order to reduce the likelihood of SC-related road accidents, it is essential to understand which areas of psychomotor performance are most affected by these substances, as well as the severity of impairment. For this purpose, a multiple database-literature review of recent experimental studies in humans and animals regarding the psychomotor effects of SCs has been performed. Despite the many limitations connected to experimental studies on humans, results showed a consistency between animal and human data. SCs appear to impair psychomotor performance in humans, affecting different domains related to safe driving even at low doses. Cases of DUI of SC have been repeatedly reported, although the exact prevalence is likely to be underestimated due to current analytical and interpretative issues. For this reason, an accurate physical examination performed by trained and experienced personnel has a primary role in recognizing signs of impairment in case of strong suspicion of SC consumption. The identification of a suspected case should be followed by reliable laboratory examination.

KEYWORDS
psychomotor performance, driving ability, driving impairment, synthetic cannabinoids, Spice

Introduction

Synthetic cannabinoids (SCs) are a large group of new psychoactive substances (NPS), chemically designed to mimic the effects of the natural cannabis (1), although generally with higher affinity to the cannabinoid receptors (CB1 and CB2) and potency compared to delta-9-tetrahydrocannabinol (THC). Recreational use of SCs has increased globally over the past few years, due to availability, easy trafficking, perceived legal status and lack of detection at routine screening (2-4).
The spreading of SCs has caused growing concern (5), requiring the attention of the European Monitoring Center for Drugs and Drug Addiction, which has so far monitored more than 224 compounds (6). The continuous introduction into the market of NPS of new and powerful synthetic molecules makes it difficult for forensic toxicologists to “keep up with the times” (7, 8). Indeed, these substances are rarely detected by common screening methods and require target methodologies (9), which have to be constantly updated. Furthermore, as for other NPS, not all the available molecules are currently regulated under national or international legislations, e.g., schedule 1 substances in the United States, the law on NPS (Neue-psychoaktive-Stoffe-Gesetz or NpSG) in Germany, the DPR 309/90 and updates in Italy, making some SCs legal. Typical symptoms following the consumption of SCs include nausea, vomiting, tachycardia, agitation, psychomotor agitation, seizures (10), but also respiratory depression, which have been reported in cases of fatal and non-fatal intoxications (11, 12). Feeling of euphoria, being “high” and “stimulated,” but also somnolence and minimal dizziness or confusion were reported by subjects consuming SCs (13, 14). Several cases of driving under the influence (DUI) involving NPS have been also reported in literature (15–17). Between January 2019 and April 2020, 62% out of 670 NPS toxicity case reported to the UNODC were classified as DUI (18). Driving is a structured process that requires the cooperation of multiple cognitive and psychomotor functions, organized in different levels of complexity (19). Each of these cognitive and psychomotor functions can be affected by ingestion, inhalation, absorption, or injection of drugs or medications (20) including SCs. While several studies are focused on alcohol and classic drugs effects on driving ability, there is a lack of knowledge regarding the effects related to SCs. In order to reduce the likelihood of SC-related road accidents, it is fundamental to understand which areas of psychomotor performance are most affected by these substances as well as the severity of impairment. To this scope, in the present study, a literature review regarding the psychomotor effects connected to SCs has been performed.

Materials and methods

A first literature search was conducted using the most common databases (PubMed, Scopus, Web of Science), focusing on both cognitive and executive functions needed for safe driving. Then, a search focused on the SC-related driving skills impairment was performed by combining phrase keywords including “synthetic cannabinoids” OR “SC” OR “Spice” AND one of the followings: “psychomotor performance,” “driving skills,” “driving ability,” “executive functions,” “motor function,” “memory,” “attention.” The following studies were included: preclinical and clinical trials, randomized controlled trials, studies performed on humans or animals published in the last 10 years (from 2012 to 2022). Real cases of DUI were also included in the literature revision, but only when SCs were confirmed on blood and data was extractable. This temporal limit was set in order to provide a review of the most recent evidence on the topic. Non-systematic reviews, studies where SCs were administered together with other substances, intoxication cases with no mention of DUI and papers with no full-text available were excluded from this study. The search was not restricted to English language documents. Results were then summarized in two separate tables for a better data overview. For studies performed on animals, functions examined, authors, years of publication, testing methods (i.e., type of tests administered), treatment parameters (i.e., substance and doses) and main findings were extracted from the included papers. For studies performed on humans, similarly the following data was extracted: functions examined, authors, years of publication, number of participants, testing methods, treatment parameters, main findings. For DUI cases, author, number of cases, age and sex of the participant, results of the toxicological analyses on blood for SCs and for other substances as well as the impairment in psychomotor performances relevant for driving, as emerged from clinical examination/police reports, drug experts’ evaluation, etc., were extracted.

Results

After the search with the selected terms, more than 500 hits, duplicates excluded, were identified. Thirty-five studies met the inclusion criteria, eight of which were performed on humans (21–28) and 27 on animals (mice) (29–55). Detailed information is described in Table 1 and in Table A of Supplementary material for human and animal studies collected, respectively. Additionally, 13 articles reported cases of DUI of SCs (56–68). Papers focused on humans tested several domains related to safe driving, which included cognitive and integrative functions (visuospatial and executive functions, attention, memory, planning, information processing speed, response inhibition), emotional processing and motor performance. All these domains were examined using validated neuropsychological tests. Three of the eight papers collected were randomized controlled trials in which vapor inhalation of JWH-018 or placebo were administered, five studies used test administration only, in the absence of a control. Administered doses of JWH-018 were fixed (2 or 3 mg) or calculated according to body weight (75 µg/kg). The number of subjects examined in each study ranged from 6 to 145 with a median of 48. Three papers involved occasional users, three chronic SCs users compared with regular cannabis users and non-users, and two included chronic SCs users and non-users. Results showed impairment in motor coordination, attention, working and long-term memory and lower speed-accuracy efficiency and response speed, together with impaired executive, cognitive and visuospatial functions,
### TABLE 1  Studies performed on humans.

| Functions                                                                 | Ref. | P. number | Testing methods                                                                                           | Treatment | Results                                                                                           | Type of users                  |
|---------------------------------------------------------------------------|------|-----------|-----------------------------------------------------------------------------------------------------------|-----------|---------------------------------------------------------------------------------------------------|-------------------------------|
| Concentration; memory; language; visuoconstructional skills; conceptual thinking; calculation; orientation; executive functions; attention speed; motor speed; visual search speed; ordering skills; mental flexibility; persistence; response inhibition; susceptibility to interference; verbal attention; continuous and selective attention |      |           | Montreal Cognitive Assessment (MOCA) Test, Verbal Memory Processes Test (VMPT), Clock Drawing Test, Cube Drawing Test, Trial Making Test, Verbal Fluency Test, Digit Span Test, Continuous Performance Test (CPT), Stroop Test, Go/No-Go Test | –                     | More severe impairments in attention, memory, executive and visuospatial functions in the SC group than in the cannabis and the healthy control groups | Chronic SCs users, chronic cannabis users, non-users |
| Executive functions; emotional processing; depression and anxiety traits   | (28) | 122       | Beck depression inventory (BDI), Spielberg state-trait anxiety inventory (STAI), Stroop word-color task, N-back task, free-recall memory task | –                     | In the SC group impairments in working/long-term memory, response inhibition. Higher ratings of depression and anxiety | Chronic SCs users, chronic cannabis users, non-users |
| Working memory; response inhibition; depression and anxiety traits         | (27) | 33        | Working memory N-back task, response-inhibition Go-No-Go task, Beck depression inventory (BDI), State-trait anxiety inventory (STAI) | –                     | In SC group higher ratings on the BDI, STAI compared with control participants. SC impaired performance on the N-back task, but not on the Go-No-Go task | Chronic SCs users, non-users |
| Cognitive performance; attention; executive functions; planning; memory; subjective experience | (25) | 6         | Digit symbol substitution task (DSST), Critical tracking test (CTT), Divided attention task (DAT), Stop signal task (SSS), Tower of London (TOL), Spatial memory task (SMT), Subjective high, Profile of moods states (POMS), Bowdle visual analog scales, marijuana craving questionnaire (MCQ), Sensitivity to Cannabis Reinforcement Questionnaire (SCRQ), Clinician-administered dissociative States Scale (CADSS) | Inhalation JWH-018 (2–3 mg) or placebo | JWH-018 impaired motor performance (CTT), divided attention (DAT) and response inhibition (SST), particularly after the 2 mg dose. Executive functioning (TOL), spatial memory (SMT), speed and information processing (DSST) were not affected by JWH-018 | Occasional cannabis users |

(Continued)
### TABLE 1 (Continued)

| Functions                                                                 | Ref. | P. number | Testing methods                                                                 | Treatment                                                                 | Results                                                                 | Type of users          |
|----------------------------------------------------------------------------|------|-----------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------|
| Cognitive performance; attention; executive functions; memory; subjective experience | (26) | 17        | Digit symbol substitution, DSST, critical tracking task, CTT, divided attention task, DAT, stop signal task, SST, Tower of London TOL, spatial memory task, [SMT], Profile of Mood States [POMS], Bowdle visual analog scales, Marijuana Craving Questionnaire [MCQ], Sensitivity to Cannabis Reinforcement Questionnaire [SCRQ], Clinician-Administered Dissociative States Scale [CADSS] | Inhalation of JWH-018 (2–6.2 mg, average 3.95 mg) or placebo             | Lower CTT, SST, SMT scores in CS group. No significant effects in DAT, TOL, and DSST. Large variability in the subjective response to the drug | Occasional cannabis users |
| Visuospatial functions; executive functions; attention; working memory; speaking; abstract thinking; hand preference; motor speed; information processing speed | (23) | 63        | Montreal Cognitive Assessment (MOCA) test, Edinburgh Handedness Inventory (EHI), Finger-Tapping Test (FTT), Adult Memory and Information Processing Battery-B form (AMIPB-B) | –                                                                        | SC group scored worse in AMIPB-B, MOCA, and FTT                         | Chronic SCs users, non-users |
| Executive functions; emotional processing; depression and anxiety traits | (24) | 94        | N-back task, Go/No-Go task, Wisconsin Sorting Card-like Task (WSCT), emotional face recognition task, questionnaires of depression, anxiety and schizotypal traits | –                                                                        | SC group scored worse on the N-back working memory task and WSCT cognitive flexibility task; showed greater schizotypal traits and symptoms and higher scores on depression and state-trait anxiety measures | Chronic SCs users, chronic cannabis users, non-users |
| Motor coordination; attention; memory; speed-accuracy efficiency; response speed; motor impulsivity; reflection impulsivity; planning | (21) | 24        | Critical Tracking Test (CTT), VAS, Divided Attention Task (DAT), Spatial Memory Task (SMT), Stop Signal Task (SST), Matching Familiar Figures Test (MIFFT), Digit Symbol Substitution Task (DSST), Tower of London (TOL), subjective high | Inhalation of JWH-018 (75 µg/kg plus booster dose of 50 µg/kg, average 5.52 mg) or placebo | Maximum subjective high 30 min after administration, maximum blood concentration after 5 min (8 ng/mL). Impaired motor coordination, attention, memory: Lower speed-accuracy efficiency, slowed response speed in a 4-h window after administration, most strongly within the first 2.5 h | Occasional cannabis users |

Ref., reference number; P. number, participants’ number.
response inhibition and information processing in SCs users (more details in Table 2). Experiments performed on animals involved mice in all the studies collected. The included articles focused primarily on memory (working, reference, spatial and recognition memory) sensorimotor performance and locomotor activity. The latter was the most commonly studied function, evaluated in 24 out of 27 studies, even when no other psychomotor performances were considered. Two studies were performed on adolescent animals, in order to assess the effects of SCs on learning and behavior once they become adults. SCs were administered by intraperitoneal injections or by exposition to smoke from a mixture containing the compounds. Impairment in psychomotor performance was described in all the studies, especially regarding locomotor activity and sensorimotor performance. DUI cases reported 1–24 cases (mean 8), for a total of 53. Subject had a mean age of 25 years (from 16 to 48) and were predominantly male, except for 2 cases. Other substances, beside SCs, were detected in 35 cases. When quantifies, SCs were in the low nanogram range, 0–3 ng/ml, though some exceptions were reported (maximum level was described for JWH-122: 73 ng/ml). The evaluation of subjects also included a wide range of parameters, including movements, coordination, balance, speech, eye movements (pupils and convergence), mood, reaction times, and type of accident/driving offense as well as the performance at tests such as Romberg, finger-to-nose (FTN) and finger-to-finger (FTF), walk-and-turn (WAT) and one leg stand (OLS) tests. Detailed information is described in Table 2.

Discussion

Our study aimed at reviewing the current literature regarding the effects of SCs on cognitive and psychomotor functions involved in driving ability. As emerged from the present literature, the number of studies investigating and demonstrating such effects is still limited, so that the understanding of the effects of SCs on psychomotor performance remains mainly based on animal data or, in humans, on self-reports and overdoses (7). Although animal data were more abundant and assessed a wide range of performances relevant for driving, it has to be reminded that the inference from animal models to humans presents several limitations and should be performed with caution (69). Indeed, dose translations, as demonstrated in clinical trials, cannot be based only on the weight, but would require a careful evaluation of more data (including oxygen use, basal metabolism, caloric expenditure, distribution and blood volume, plasma proteins, and renal function) (70). To partially overcome this limit, human equivalent doses should be calculated on the basis of the body surface area, although further research is needed to provide more appropriate conversions. Beside doses, the evaluation of psychomotor function in mice are different and might not correspond to the experimental tests performed on humans, which again might not reproduce the impairment in real-driving. As demonstrated for other compounds and NPS (69), the limitedness of studies on humans is partially connected to the ethical challenges related to the administration to healthy volunteers of potent compounds with possible unpredictable effects on one hand. Indeed, in order to reduce potential negative effects, the randomized controlled trials included in the present study typically involved “occasional users” and not naïve subjects (21, 25, 26). This might lead to an underestimation of the effects of SCs due to a developed tolerance. Moreover, aiming at predicting effects and reducing harm to subjects, in this kind of studies JWH-018, one of the first generation of SCs, was administered. However, JWH-018 has been substantially abandoned as recreational drug since many years, and replaced by novel generation molecules, often characterized by higher potency (71, 72), so that the effects on driving of the more widespread and potent SCs remains unknown. Only a few randomized control trials (RCTs) performed on humans were found and these studies involved a small sample size, so that it is hard to make generalizations to the whole populations. Many factors remain largely unexplored, e.g., the impact of co-administered drugs. Finally, as underlined by Theunissen et al. (21, 26), blood levels in controlled studies (∼8 ng/ml of JWH-018) are far below the concentrations reported in real cases, when other factors, such as multiple administrations, different administration routes, and tolerance, also have an impact on the severity of the impairment as well as on the duration of the effects. The large number of molecules available, the absence of routine toxicological screenings effective for their detection, the lack of labeled analytical reference standards and the high potency of these compounds, which often leads to very low concentration in tissues, are factors that make the identification and quantification of SCs, in real driving cases and epidemiological studies, complex and strictly dependent on laboratory techniques and instrumentation (8). These factors could inevitably lead to an underestimation of DUI related to SCs consumption due to false negative results. Currently, liquid chromatography-tandem mass spectrometry (LC-MS/MS) together with Liquid chromatography with quadrupole time of flight mass spectrometry (LC-QTOF-MS) represent the methods of choice for the recognition of NPS and SCs in multiple biological matrices, offering sensitive and specific identification and allowing for their quantification (73–79). LC-QTOF-MS might lack the sensitivity required to detected very low SCs concentrations, as expected given the limited half-life of compounds and the potential delay in blood collection. However, it allows an untargeted screening involving emerging compounds (80). By using LC-QTOF-MS coupled with LC-MS/MS, Fels et al. found the presence of SCs in 12 of 837 blood samples collected from suspected German DUI cases in 2017–2018 (59). Similar results are described in literature from samples obtained during police checks or
### TABLE 2 Cases of DUI of SCs.

| Ref. | Cases | Age, sex | SC blood levels (ng/ml) | Other drugs | Psychomotor performances relevant for driving |
|------|-------|----------|-------------------------|-------------|---------------------------------------------|
| Lemos (56) | 1 | 22, M | XLR-11: 1.34 | – | Slow body movements and coordination, slow, low and mumbled speech, lethargy, droopy eyelids, stiff and rigid muscle tone, lack of convergence, impaired OLS, unable to maintain balance at the WAT, no coordination at the FTN test |
| Yeakel and Logan (57) | 12 | – | JWH-018: 1.1 | – | WAT: arm raising, swayed, improper turn. OLS: flexed foot, arm raising. Slow reaction times |
| 18 | JWH-018: 0.24 | – | – | – | WAT: arm raising, improper turn. OLS: arm raising. Romberg: eye flutters |
| 22 | JWH-018: 9.9 | – | JWH-250: 2.7 | – | HGN |
| 25 | JWH-018: pos | – | – | – | OLS: swaying movements, arm raising, tremors. Romberg: rapid eyelid and hand tremors |
| 18 | JWH-018: pos | – | – | – | WAT: loss of balance. OLS: incorrect counting, swaying movements, leg tremors. Romberg: leg, eye tremors |
| 31 | AM-2201: 1.4 | Caffeine, theobromine, nicotine and cotinine | JWH-081: 0.12 | – | WAT and OLS: swaying movements, arm raising. Romberg: eye tremors |
| 27 | JWH-018: 2.5 | – | JWH-210: pos | – | Romberg: eye tremors |
| 21 | AM-2201: 0.43 | – | JWH-250: 0.38 | – | WAT: leg, body tremors. OLS and Romberg: swaying movements, tremors |
| 26 | AM-2201: 0.94 | – | – | – | – |
| 18 | AM-2201: 3.6 | – | – | – | WAT: arm raising, leg tremors. OLS: swaying movements, arm raising, foot down Romberg: swaying movements, leg tremors |
| 21 | AM-2201: 2.8 | – | JWH-081: pos | – | HGN. WAT: imbalance with near-fall |
| 19 | AM-2201: 0.4 | – | JWH-210: pos | – | WAT and OLS: tremors |
| Masshoff et al. (61) | 7 | 18, M | AM-2201: 4.6 | – | Inability to follow instructions, slow movements, confusion, disorientation, slurred speech, nearly unconsciousness |

(Continued)
| Ref. | Cases | Age, sex | SC blood levels (ng/ml) | Other drugs | Psychomotor performances relevant for driving |
|------|-------|----------|-------------------------|-------------|---------------------------------------------|
| 14, F |       | JWH-210: 4.0 JWH-122: 0.33 | – | Cycling in wavy lines. Instability, slurred speech, dizzy mind |
| 20, M |       | JWH-018: 1.7 JWH-122: 7.6 JWH-210: 4.4 AM-2201: 0.31 | – | Vestibular disorder, disturbance of fine motor skills, doubtful FTE, delayed pupils’ reaction to light |
| 29, M |       | JWH-210: 6.2 JWH-122: 1.0 | – | Delayed pupils’ reaction to light, dizzy mind, retarded behavior |
| 21, M |       | JWH-018: 0.52 JWH-122: 0.26 JWH-210: 0.66 | – | Delayed reactions, retarded movements, dizzy mind, no pupils’ reaction to light, nervousness and laziness |
| 21, M |       | JWH-307: 1.1 | Ethanol | Fast driving, run off the road. |
| 22, M |       | JWH-018: 1.0 JWH-122: 28 JWH-210: 2.5 AM-2201, JWH-307, MAM-2201, UR-144 pos | – | Retarded movements, nervousness, delayed pupils’ reaction to light |
| Louis et al. (62) | 18 | | | |
| 22, M |       | UR-144: pos | – | Speed, lane travel. Poor coordination, tremors, altered WAT, OLS |
| 22, M |       | UR-144: pos | – | Lane travel. Poor coordination, slurred speech, lack of convergence, tremors, altered WAT, OLS |
| 25, M |       | UR-144: pos | – | Unconscious, accident. Shaking coordination, slurred speech, tremors |
| 42, M |       | UR-144: pos | – | Lane travel. Poor coordination, slurred speech, lack of convergence, altered WAT, OLS |
| 29, M |       | UR-144: pos | – | Erratic driving. Poor coordination, droopy eyelids, slurred speech, tremors, altered WAT, OLS |
| 30, M |       | UR-144, XLR-11: pos | – | Speed, lane travel. Poor coordination, slurred speech, tremors, altered WAT, FTN |
| 22, M |       | UR-144, XLR-11: pos | – | Lane travel. Lack of convergence, tremors, altered OLS, FTN |
| 23, M |       | UR-144, XLR-11, AM-2201, JWH-018, JWH-022: pos | – | Lane travel. Poor coordination, slurred speech, altered WAT, OLS |
| 30, M |       | UR-144, XLR-11: pos | – | Accident. Lack of convergence, tremors, altered OLS, FTN |
| Ref. | Cases | Age, sex | SC blood levels (ng/ml) | Other drugs | Psychomotor performances relevant for driving |
|------|-------|----------|------------------------|-------------|---------------------------------------------|
| 25, M | UR-144: pos | - | Lane travel. Swaying movements, slurred speech, lack of convergence, tremors, altered WAT, OLS |
| 27, M | XLR-11: pos | - | Speed, lane travel, accident. Slurred speech |
| 27, M | XLR-11: pos | - | Speed, lane travel, driving on curb, accident. Poor coordination, slurred speech, lack of convergence, tremors, altered WAT, OLS, FTN |
| 30, M | XLR-11: pos | - | Moving violation. Altered WAT, OLS |
| 17, M | XLR-11: pos | - | Lane travel. Poor coordination, altered WAT |
| 22, M | XLR-11: pos | - | Unconscious, accident. Poor coordination, slurred speech, altered WAT, OLS |
| 19, M | XLR-11: pos | - | Poor coordination, slurred speech, lack of convergence, tremors, altered WAT, OLS, FTN |
| 22, M | XLR-11: pos | - | Driving on curb. Slow coordination, droopy eyelids, tremors, altered WAT, OLS, FTN |
| 23, M | XLR-11: pos | - | Driving in the wrong way. Poor coordination, lack of convergence, tremors, altered WAT, OLS, FTN |

Tuv et al. (63) 16

| Ref. | Cases | Age, sex | SC blood levels (ng/ml) | Other drugs | Psychomotor performances relevant for driving |
|------|-------|----------|------------------------|-------------|---------------------------------------------|
| 48, M | JWH-081: 0.19 | Amphetamine, methamphetamine, BDZ | Mild impairment |
| 35, M | JWH-250: 0.47 | Amphetamine, methamphetamine, BDZ | Moderate impairment |
| 29, M | JWH-018: 0.24 | Amphetamine, methamphetamine, THC | No impairment |
| 17, M | AM-2201: 0.07 | Methamphetamine, BDZ | Mild impairment |
| 20, M | RCS-4: 1.0 | BDZ, THC | Mild impairment |
| 25, M | JWH-122: 1.2 | THC | No impairment |
| 31, M | AM-2201: 0.25 | methamphetamine, BDZ, THC | - |
| 35, M | JWH-018: 0.13 | Amphetamine, methamphetamine, BDZ, THC | Mild impairment |
| 30, M | JWH-018: 0.10 | BDZ, THC | - |
| 41, M | AM-2201: 0.28 | BDZ, THC, methadone | - |
| 33, M | JWH-018: 0.46 | Methamphetamine, BDZ | No impairment |
| 29, M | JWH-122: 0.50 | Ethanol, THC, LSD | Traffic accident |
| 27, M | JWH-122: 1.67 | THC, ketamine, LSD | Traffic accident |
| 26, M | JWH-018: 0.08 | BDZ, THC | Traffic accident. Severe impairment |
| 30, M | AM-2201: 0.4 | BDZ, methylphenidate, THC | Severe impairment |
| 16, M | AM-2201: 1.33 | BDZ, THC | Mild impairment |

(Continued)
### TABLE 2 (Continued)

| Ref.         | Cases       | Age, sex | SC blood levels (ng/ml) | Other drugs | Psychomotor performances relevant for driving |
|--------------|-------------|----------|-------------------------|-------------|-----------------------------------------------|
| Kaneko (64)  | 6 (others with no blood confirmation) | 25, M    | AM-232: pos              | –           | Speed driving and accident. Blurred vision, abnormal posture, no crash memory |
|              | 24, M       | 5F-PB-22: 0.27 | –                        | –           | Lane travel and frontal collision. Loss of consciousness, no crash memory |
|              | 38, M       | 5F-PB-22: 0.39 | –                        | –           | Driving on curb, continued accelerating after impact with pedestrians, moving the steering wheel and gear lever in a stereotyped manner, no crash memory |
|              | 37, M       | FUB-PB-22: 1.74 | –                        | –           | Car accident. Slow movements, impaired consciousness, excited and agitated, no crash memory |
|              | 28, M       | 5F-AMB: pos | –                        | –           | Ignoring red light and collision. Motionless, unresponsiveness, no crash memory |
|              | 26, M       | 5F-AMB: 0.07 FUB-PB-22: 0.79 | –                        | –           | Car accident. Impaired consciousness, no crash memory |
| Kleis et al. (65) | 1 | 29, M | 5F-MDMB-PICA metabolite: pos | – | Traffic offense. Balance deficits, staggering, pupils’ unresponsiveness to light, lethargy slow reactions, aggressive behavior, numbness |
| Jaenicke et al. (66) | 12 | 24, M | JWH-122: 73.05 | – | Delayed pupils’ reaction to light, eyelid twitching, impairments of FTF and Romberg tests, change in time perception |
|              | 19, M       | JWH-250: 0.81 JWH-122: 9.53 | –                        | –           | Slight delayed pupils’ reaction to light, impairment of FTF |
|              | 46, M       | JWH-015: pos | Ethanol                   | –           | Agitation, eyelid twitching, impairment of FTF; knees slightly tremulous, unsteady mood |
|              | 18, M       | JWH-250: 0.21 | THC                       | –           | Slight delayed pupils’ reaction to light, impairment of FTF |
|              | 25, M       | JWH-250: 2.94 JWH-015: pos JWH-018: 0.75 JWH-122: 1.3 | THC                       | –           | Delayed pupils’ reaction to light, light eyelid twitching, tremor, impairment of Romberg test |
|              | 21, M       | JWH-122: 0.11 | THC                       | –           | (Continued) |

(10.3389/fpsyt.2022.965858)
| Ref.          | Cases | Age, sex | SC blood levels (ng/ml) | Other drugs                  | Psychomotor performances relevant for driving                                                                 |
|---------------|-------|----------|-------------------------|------------------------------|---------------------------------------------------------------------------------------------------------------|
| McCain et al. | 45, M | 5F-ADB metabolite: 26.37 |                         | –                            | Driving against the traffic and swerving the vehicle into a roadside guard rail. Loss of consciousness, nystagmus, WAT and OLS impaired |
| Kraemer et al. | 26, M | 5F-ADB: 0.19 |                         | –                            | Erratic driving, lane travel. Mood alterations, retarded/delayed pupils’ reaction                              |
| Peterson and Couper (58) | 22, M | AB-PINACA: 27.8 |                         | –                            | Traffic accident. Confusion, slurred speech, shaking, impaired WAT and OLS                                    |
| Same subject  |       | AB-PINACA: 10 |                         | –                            | Vehicle stopped in the roadway. Inability to stand.                                                          |
| Same subject  |       | AB-CHMINACA: 9.1 |                         | –                            | Erratic driving                                                                                                                                                          |
| Same subject  |       | AB-CHMINACA: 4.5 |                         | –                            | Slow lethargic movements, inability to maintain balance                                                      |
| –             |       | AB-PINACA: 2.6 AM-2201: 2.1 JWH-210: 0.2 |                         | –                            | Lack of convergence, slightly impaired WAT and OLS                                                        |
| –             |       | AB-PINACA: 4.6 |                         | –                            | Lack of convergence, impaired WAT and OLS                                                                   |
| –             |       | AB-PINACA: 5.7 |                         | –                            | VGN, lack of convergence, impaired WAT and OLS                                                              |
| –             |       | AB-PINACA: 8.3 |                         | –                            | OLS slight impairment                                                                                        |
| –             |       | AB-PINACA: 9.1 |                         | –                            | No impairment                                                                                               |

(Continued)
| Ref. | Cases | Age, sex | SC blood levels (ng/ml) | Other drugs | Psychomotor performances relevant for driving |
|------|-------|----------|-------------------------|-------------|---------------------------------------------|
| –    | AB-PINACA: 9.1 | – | – | Lack of convergence, impaired WAT and OLS |
| –    | AB-PINACA: > 10 | – | – | Lack of convergence, eyelid tremors, impaired WAT and OLS |
| –    | AB-PINACA: > 10 | – | – | Lack of convergence, eyelid tremors, impaired WAT and OLS |
| –    | AB-PINACA: > 10 | – | – | Lack of convergence, impaired WAT and OLS |
| –    | AB-PINACA: 41.3 | – | – | Lack of convergence, impaired WAT and OLS |
| 38, M | AB-CHMINACA: 2.3 | – | – | Vehicle blocking the roadway. Lethargy, confusion, imbalance, HGN, lack of convergence, impaired WAT and OLS |
| 19, M | AB-CHMINACA: 7.1 | Diphenhydramine | Asleep at wheel. Slurred speech, swaying movements, instability |
| Same subject | AB-CHMINACA: 7.1 | Diphenhydramine | Poor driving. Impaired WAT and OLS |
| –    | AB-CHMINACA: 1 | THC | HGN |
| –    | AB-CHMINACA: 2.4 | – | – | Impaired WAT and OLS |
| –    | AB-CHMINACA: 3.5 | – | – | Impaired WAT and OLS |
| –    | AB-CHMINACA: 4.4 UR-144: 0.3 SF-ABPINACA: 0.4 | – | – | HGN, WAT, and OLS slightly impaired |
| –    | AB-CHMINACA: 6.3 | – | – | No impairment |
| –    | AB-CHMINACA: 7.3 | – | – | Eyelid tremors, impaired WAT and OLS |
| –    | AB-CHMINACA: 9.5 | – | – | VGN, impaired WAT |
| Fels et al. (59) | 4 (others with traces only) | 23, M | 5F-ADB: 1.4 | BEC, methamphetamines | Delayed pupils' reaction to light, shaking |
| –    | 5F-Cumyl-PICA: pos | THC | Delayed pupils' reaction to light, imbalance, nervousness, restlessness |
| 19, M | MDMB-CHMICA: 0.04 | THC | Eyelid twitching, lack of concentration, shaking |
| 28, M | 5F-MDMB-PICA: 0.04 Cumyl-PEGACLONE: 0.75 | THC, BEC | Slurred speech, euphoria, restlessness |
| Adamowicz and Lechowicz (60) | 1 | 19, M | UR-144: 14.6 | – | Car accident. Hyperactive behavior, sluggish pupils' reaction to light, gait abnormalities, staggering |

DUI, driving under the influence; SCs, synthetic cannabinoids; Ref., reference number; M, male; F, female; pos, positive; BDZ, benzodiazepines; BEC, benzylecgonine; THC, delta-9-tetrahydrocannabinol; OLS, one leg stand test; WAT, walk-and-turn test; FT, finger-to-finger test; FTN, finger-to-nose test; HGN, horizontal nystagmus; VGN, vertical nystagmus. Impairment was defined in the presence of more than 1 clue.
following road accidents (56, 57, 60, 61, 63), making it possible to ascertain that SCs consumption while driving is a widespread reality. For this reason, it is important to request in-depth examinations whenever there is a suspicion of SCs intake, even when first routine examinations test negative. Another interesting topic of debate consists in the correlation between toxicological findings and impairment in driving abilities. Blood has always been the matrix of choice for DUI cases, because it usually correlates with the effects at the central nervous system and with the driving impairment. However, analytical inconsistencies and different timings of sampling (being blood not collected on site), might impair the opportunity to compare cases of DUI due to SCs. The blood or alternative matrix correlation to driving abilities for SCs has yet to be better evaluated (81).

SCs and psychomotor functions in animals

One of the advantages of animal studies is certainly the possibility of testing a wider panel of compounds. Indeed, in the studies included in the present review, synthetic cannabinoids pertaining to the so-called “third generation” of SCs were tested, i.e., composed by a four-substructure pattern (tail–core–link–ring) resembling JWH-018, but with a substituent at any of these substructures (82).

The influence of SCs on spontaneous locomotor activity was proven by static (bar test) and dynamic conditions (drag and accelerod test) with the strongest reduction in the distance traveled with JWH-018 at 6 mg/kg (45–47). At the accelerod tests, 5F-AKB-48 induced a prolonged and significant locomotion impairment at doses of 3 mg/kg, while the non-fluorinated analog required higher doses (6 mg/kg) to produce only transient effects (30). Hypomobility was also shown by nose-only exposure to a mixture of JWH-018 and other SCs (50). High doses of AB-FUBINACA (3–4 mg/kg) and PB-22 (0.4 mg/kg), produced a dose-dependent decrease of locomotor activity in the staircase paradigm, while AB-CHMINACA showed effects at 0.5–1 mg/kg (49). Interestingly, systemic injection, but not intracerebroventricular injection of 5F-AMB produced impairment of locomotor activity, suggesting a peripheral effect (41).Sensorimotor studies mainly focused on visual, acoustic and tactile responses (30, 46, 47). The halogenated compounds tested by Bilel et al. (JWH-018-Cl, JWH-018-Br, and AM-2201) altered sensory and motor parameters in a dose-dependent manner, though JWH-018-Br appeared less potent than the others in tactile responses (46). AKB-48 and 5F-AKB-48, 5F-ADBINACA, AB-FUBINACA, and STS-135 affected the stalrte response to visual, acoustic, and tactile stimuli in mice but were less effective than JWH-018 (30, 47). In the studies of Canazza et al. (30) and (47) the administration of JWH-018, AKF-48, 5F-AKB-58, 5F-ADBINACA, AB-FUBINACA, and STS-135 induced sensorimotor alterations as well as convulsions, hyperreflexia, tail elevation and aggressive behavior. The memory function and spatial learning ability were evaluated by Schreiber et al. (49) though the Y-maze paradigm, showing an impairment under high doses of AB-FUBINACA (4 mg/kg) and even low doses of AB-CHMINACA (0.125 mg/kg) and PB-22 (0.05 mg/kg). Recognition memory was impaired by the administration of 5F-AMB but only in the acquisition, and not in the recall (41), suggesting that subjects might be able to recall previously experienced environmental contents. Cha et al. showed no effect of JWH-081 and JWH-210 (both at 0.1–5 mg/kg) on learning and memory (51). On the contrary, Barbieri et al. demonstrated an effect of JWH-018, JWH-018-Br and JWH-018-Cl on working memory as observed by the novel object recognition test (NOR) (48). Spatial memory, tested though the Morris water maze test, was impaired after 0.25 mg/kg intraperitoneal injection of CP55,940 (32). Similar results have been reported from Basavarajappa et al., with 1.25 mg/kg of JWH-081 impairing memory in the NOR test and in the Y maze (31). Recognition memory impairment in the NOR was also reported together with “tetrad effects” by Canizzaro et al. after 3 mg/kg APICA intraperitoneal injection (54). Memory impairment at the Morris water maze was also described in adult mice treated with WIN55212.2 during adolescence (37). Musa et al. reported a higher anxiety-like and compulsive-like state in adulthood after a 5F-MDMB-PICA exposure during adolescence (39).

Taken together, these results allowed to confirm an effect of SCs on several functions (locomotor activity, spatial memory, sensorimotor functions) on animals. Moreover, these studies suggest that, although all SCs have an effect on cannabinoid receptors and pertain to the same NPS group, the nature and severity of their effects might differ from one molecule to the other.

SCs and psychomotor functions in humans

Despite the limitations connected to epidemiological and experimental studies, it has to be noted that all the collected articles described some grade of impairment in either cognitive or psychomotor performances after the administration of SCs. Particularly, JWH-018 at doses from 2 mg impaired motor coordination as evaluated by the Critical Tracking Test and attention as demonstrated by Divided Attention Task and Stop Signal Task (21, 25, 26). By increasing the dose to 75 µg/kg (average dose 3.95 mg) and by applying a booster of 50 µg/kg (average dose 5.52 mg) when no subjective response was seen, spatial memory and impulsivity (as demonstrated
by the Matching Familiar Figures Test) were also affected (21, 26). The latter is an important function, corresponding to the ability of problem-solving functions, which could be relevant for operating a vehicle and particularly for the avoidance of crashes. Other executive decision-making or attentional tests, previously shown to be sensitive for cannabis, such as the Digit Symbol Substitution Task or the Tower of London, were not affected by JWH-018 administration, with the maximal doses reported (21, 25, 26). Impairment was mostly comparable to the administration of 250–300 µg/kg of cannabis (7), which doses have been however demonstrated to increase the risk of road accidents. The manual motor speed was affected both with the dominant and the non-dominant hand in a group of SCs chronic users compared to controls (23). Attention and memory were impaired in SC users also, while attention functions were mostly preserved in cannabis use disorder (22, 24, 28), as evaluated by several tests such as the Digit Span Test, the Trial Making Test B, the Go/No Go Test, the Stroop test, and the Verbal Memory Processes Test. Executive functions (e.g., reaction time, commission and omission errors, impulse and reaction inhibition, changing strategies, mental flexibility, planning, visual spatial skills, organizing thoughts) and visual-spatial perception functions (e.g., Cube Drawing Test and Clock Drawing Test), usually conserved in cannabis users, were affected by SCs use disorder (22, 24, 28). This type of studies pointed toward an impairment of the mental flexibility, working memory and response inhibition in chronic SCs users (24, 28) and a general cognitive impairment as assessed by the Montreal Cognitive Assessment (MOCA) test (23). However, studies performed on SCs users did not test the concentrations in blood or urine and did not evaluate an acute effect (subjects were tested after 3 days of reported abstinence), but only the long-term one on cognitive functions, so that several confounding factors, e.g., treatment, past cannabis consumption history, other drugs consumption history, psychiatric diseases, abstinence time and withdrawal could have altered the results. On the basis of the studies involved in the present review, a risk for road accidents appear to involve both occasional and chronic SCs users. Regarding the clinical signs of impairment, the epidemiological data available in literature are in agreement with the experimental studies collected in this review. Among cases of DUI, a wider panel of SCs was detected on blood, including third generation SCs. Adamowicz and Lachowicz described a hyperactive behavior, gait abnormalities and staggering reported by the officers who first examined a SC consumer after a traffic accident. The accident occurred at 6:30 p.m., two and a half hours after the SC consumption (60). This data is consistent with the findings by Theunissen et al. describing the maximum psychomotor impairment within the first 2.5 h (21). It is interesting to note that the subjective high peaked 30 min after the administration, while a slowed response speed was seen until 4 h after consumption, suggesting a limited self-awareness of driving inability (21). Large variability in the subjective effects was also reported (26). In a Japanese paper collecting data from SC-related road accidents, “impaired consciousness” was described in most of the cases, with blurred vision, slowed motor activity, coordination and short memory impairment (64). Lemos et al. reported one case of DUI of the synthetic cannabinoid XLR-11 (quantified at 1.34 ng/ml). The driver was involved in a traffic collision, presented slurred speech, impaired attention and slowed movements, was unable to maintain balance and to perform the FTN correctly (56). Musshoff et al. described 7 cases of DUI with SCs, and the following findings were noted by the police or physicians visiting drivers: inability to follow basic instructions, vestibular disorders, delayed reactions of pupils to light, slowed movements, alterations in speech and in consciousness (61). Louis et al. reported 18 cases of DUI under the influence of SCs showing impairment of speech, coordination, eye convergence as well as alteration in the WAT and OLS (62). Another interesting finding was that SC-abused drivers might not remember the collision scene (64). Compared to cannabis user, persons arrested for driving under the influence of SCs were more confused, disoriented, incoherent, and showed slurred speech (83). Traffic offenses reported to SCs-intoxicated drivers ranged from erratic driving, lane traveling, speed driving, driving on curb, ignoring red lights until falling asleep, off roads, car accidents with or without pedestrian collisions (58, 63, 84). Similar findings, and psychomotor impairment, were noted from very low blood/serum/plasma levels, although the comparison between studies is limited by analytical issues as well as the different sampling times. Another point to consider is that NPS might be consumed in a setting of polydrug use, resulting in possible synergies and amplification of the effects (59, 61, 66, 84). In a recent paper, Funada et al. demonstrate that ethanol-induced motor impairments are enhanced when consumed with SC (85). However, further studies are needed to establish if and how much multiple consumption affects safe driving. Finally, studies performed on the road or by using an advanced driving simulator would bring a more truthful picture of the SC-related psychomotor impairment.

Conclusions

Cases of DUI of SCs have been increasingly reported, although the exact prevalence of the phenomenon is likely to be underestimated. It is important to recognize signs of impairment through physical examination by trained and experienced personnel and to perform a thorough examination when there is a strong suspicion of SCs consumption, even when standard screenings test negative. Target LC-MS/MS methods are currently the most reliable technique for the detection and quantification of SCs in human specimens and should be preferred in these investigations. LC-QTOF-MS qualitative methods might also be helpful, allowing to search specifically for
a wide range of new emerging substances. As demonstrated by animal and human experimental studies (from doses of 2-3 mg) and by studies on SCs users, SCs impair several psychomotor domains and psychomotor performances in humans, including motor performances, attention, memory, spatial memory, executive functions, and visual-spatial perception function. The impairment reported by these studies was confirmed by real cases of DUI of SCs, where subjects displayed a range from none to severe impairment (inability to stand, imbalance, lack of coordination, unconsciousness, etc.) with low SCs concentrations detected. Furthermore, several traffic offenses were reported and allowed to assess the effect of these substances on road, highlighting that SCs consumption represents a major problem for road safety.

**Data availability statement**

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

**Author contributions**

AG, GB, and RG contributed to the conception, design of the study, and wrote sections of the manuscript. VO organized the database and wrote the first draft of the manuscript. AG supervised the final draft. All authors contributed to the manuscript revision, read, and approved the submitted version.

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Supplementary material**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyg.2022.998828/full#supplementary-material

**References**

1. Alves VL, Gonçalves JL, Aguilar I, Teixeira HM, Câmara JS. The synthetic cannabinoid phenomenon: from structure to toxicological properties — A review. *Crit Rev Toxicol.* (2020) 50:359–82. doi: 10.1080/10408444.2020.17 62539
2. Gray P, Ralphs R, Williams L. The use of synthetic cannabinoid receptor agonists (SCRAs) within the homeless population: motivations, harms and the implications for developing an appropriate response. *Addict Res Theory.* (2021) 29:1–10. doi: 10.1080/16066359.2020.1730820
3. Ralphs R, Williams L, Ashke R, Norton A. Adding spice to the Porridge: the development of a synthetic cannabinoid market in an English prison. *Int J Drug Policy.* (2017) 40:57–69. doi: 10.1016/j.drugpo.2016.10.003
4. Clancy RV, Hodgson RC, Kendurkar A, Terry MA, Dadd L, Clancy DM, et al. Synthetic cannabinoid use in an acute psychiatric inpatient unit. *Int J Ment Health Nurs.* (2018) 27:600–7. doi: 10.1111/inm.12341
5. United Nations Office on Drugs and Crime. *World Drug Report 2021.* Booklet 2 - Global Overview of Drug Demand and Drug Supply. (2021). Available online at: https://www.unodc.org/unodc/en/data-and-analysis/wdr-2021_booklet-2.html (accessed May 24, 2022).
6. European Monitoring Centre for Drugs and Drug Addiction. *Europe: Drug Report 2021: Trends and Developments.* (2021). Available online at: https://www. emcdda.europa.eu/publications/edr/trends-developments/2021_en (accessed May 24, 2022).
7. Peacock A, Bruno R, Gisv N, Degenhardt L, Hall W, Sedefov R, et al. New psychoactive substances: challenges for drug surveillance, control, and public health responses. *Lancet.* (2019) 394:1688–84. doi: 10.1016/S0140-6736(19)32231-7
8. Pichini S, Lo Faro AF, Busardó FP, Giorgianni R. Medicinal cannabis and synthetic cannabinoid use. *Medicina.* (2020) 56:453. doi: 10.3390/medicina56090453
9. Franz F, Angerer V, Jechle H, Pegaro M, Ertl H, Wittifurtner G, et al. Immunossay screening in urine for synthetic cannabinoids - an evaluation of the diagnostic efficiency. *Clin Chem Lab Med.* (2017) 55:1375–84. doi: 10.1515/cclm-2016-0831
10. Auswärter V, Dresen S, Weimann W, Müller M, Pütz M, Ferreiros N. ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? *J Mass Spectrom.* (2009) 44:832–7. doi: 10.1002/jms.1558
11. Giorgietti A, Busardó FP, Tittarelli R, Auswärter V, Giorgiotti R. Post-mortem toxicology: a systematic review of death cases involving synthetic cannabinoid receptor agonists. *Front Psychiatry.* (2020) 11:1–22. doi: 10.3389/fpsyt.2020.00464
12. Darke S, Duffou J, Farrrell M, Peacock A, Lappin J. Characteristics and circumstances of synthetic cannabinoid-related death. *Clin Toxicol.* (2020) 58:368–74. doi: 10.1080/15563650.2019.1647344
13. La Maida N, Papaset E, Martínez L, Pérez-Mañá C, Poyatos L, Pellegrini M, et al. Acute pharmacological effects and oral fluid biomarkers of the synthetic cannabinoid UR-144 and THC in recreational users. *Biolog.* (2021) 10:257. doi: 10.3390/biology10040257
14. Martínez I, La Maida N, Papaset E, Pérez-Mañá C, Poyatos L, Pellegrini M, et al. Acute pharmacological effects and oral fluid concentrations of the synthetic cannabinoids JWH-122 and JWH-210 in humans after self-administration: an observational study. *Front Pharmacol.* (2020) 12:705643. doi: 10.3389/fphar.2021.705643
15. Riceval C, Wille SMR, Nachon-Phanithavong M, Samyn N, Allorge D, Gaulier J. New psychoactive substances in oral fluid of French and Belgian drivers in 2016. *Int J Drug Policy.* (2018) 57:1–3. doi: 10.1016/j.drugpo.2018.03.013
16. Riceval C, Dumestre-Toulet V, Wiat I, Vanhoye X, Humbert L, Nachon-Phanithavong M, et al. New psychoactive substances in oral fluid of drivers around a music festival in south-west France in 2017. *Forensic Sci Int.* (2019) 297:265–9. doi: 10.1016/j.forsciint.2019.02.029
mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced in vivo effects of the synthetic cannabinoid JWH-081 and JWH-210.

36. Ossato A, Trapella C, Borelli AC, Beggiato S, et al. Synthetic cannabinoid JWH-081 and its halogenated derivatives JWH-018 and JWH-073 and their 9-Tetrahydrocannabinol-like discriminative stimulus effects of compounds commonly found in K2/Spice. Behav Pharmacol. (2014) 25:750–7. doi: 10.1097/FPB.0000000000000093

37. Tomas-Reg J, Benito E, Agis-Balboa RC, Piscitelli F, Hoyer-Fender S, Di Marzo V, et al. Chronic exposure to cannabinoids during adolescence causes long-lasting behavioral deficits in adult mice. Addict Biol. (2017) 22:1778–89. doi: 10.1111/adb.12446

38. Pinson A, Yarborough AL, Bush JM, Cabangon CV, Jackson BK, Fukuda S, et al. Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-ABK48: implications for toxicity. Pharmacol Biochem Behav. (2019) 175:17294. doi: 10.1016/j.pbb.2019.17294

39. Musa A, Simola N, Piras G, Caria F, Onaiwi ES, De Luca MA. Neurochemical and behavioral characterization after acute and repeated exposure to novel synthetic cannabinoid agonist 5-mdmb-pca. Brain Sci. (2020) 10:1–14. doi: 10.3390/brainsci10010011

40. Ossato A, Uccelli L, Bidel S, Canazza I, Di Domenico G, Pasquali M, et al. Psychostimulant effect of the synthetic cannabinoid JWH-018 and AB-FUBINACA: behavioral, neurochemical, and dopamine transporter scan imaging studies in mice. Front Psychiatry. (2017) 8:130. doi: 10.3389/fpsyt.2017.00130

41. Ito S, Deyama S, Demoto M, Zhang T, Sasase H, Fukuo A, et al. Effects of the synthetic cannabinoid 5F-AMB on anxiety and recognition memory in mice. Psychopharmacology. (2019) 236:2235–42. doi: 10.1007/s00213-019-05222-2

42. Tredler KR, Vanegas SO, Plokis JL, Kinsey SG. The short-acting synthetic cannabinoid AB-FUBINACA induces physical dependence in mice. Drug Alcohol Depend. (2020) 214:1–19. doi: 10.1016/j.drugalcdep.2020.108179

43. Gatch MB, Forster MJ. Δ9-Tetrahydrocannabinol-like discriminative stimulus effects of compounds commonly found in K2/Spice. Behav Pharmacol. (2014) 25:750–7. doi: 10.1097/FPB.0000000000000093

44. Gatch MB, Forster MJ. Δ9-tetrahydrocannabinol-like effects of novel synthetic cannabinoids in mice and rats. Psychopharmacology. (2016) 233:1901–10. doi: 10.1007/s00213-016-4327-6

45. Vigolo A, Ossato A, Trapella C, Vincenzi F, Rimondo C, Seri C, et al. Novel halogenated derivatives of JWH-018: behavioral and binding studies in mice. Neuropharmacology. (2015) 95:68–82. doi: 10.1016/j.neuropharm.2015.02.008

46. Bidel S, Turri M, Arfè R, Ossato A, Trapella C, Serpelloni G, et al. Novel halogenated synthetic cannabinoids impair sensorimotor functions in mice. Neurotoxicology. (2020) 76:17–32. doi: 10.1016/j.neuro.2019.10.002

47. Canazza I, Ossato A, Vincenzi F, Gregori A, Di Rosa F, Nigro E, et al. Pharmacological effects of the novel third-generation fluorinated synthetic cannabinoids, 5F-ADBINA, AB-FUBINACA, and STS-135 in mice. In vivo and in vivo studies. Hum Psychopharmacol. (2017) 32:1–27. doi: 10.1002/hup.2601

48. Barbieri M, Ossato A, Canazza I, Trapella C, Borelli AC, Beggiato S, et al. Synthetic cannabinoid JWH-018 and its halogenated derivatives JWH-018-C1 and JWH-018-C8 impair Novel Object Recognition in mice : behavioral, electrophysiological and neurochemical evidence. Neuropharmacology. (2016) 109:254–69. doi: 10.1016/j.neuropharm.2016.06.027

49. Schreiber S, Bader M, Lenchinski T, Meninger H, Rubовitch V, Katz Y, et al. Functional effects of synthetic cannabinoids versus a Δ 9 -THC in mice on body temperature, nociceptive threshold, anxiety, cognition, locomotor/exploratory parameters and depression. Addict Biol. (2019) 24:418–25. doi: 10.1111/adb.12606

50. Wiebelhaus JM, Plokis JL, Plokis A, Vann RE, Lichtman AH, Wise LE. Inhalation exposure to smoke from synthetic “marijuana” produces potent cannabinimetic effects in mice. Drug Alcohol Depend. (2012) 126:316–23. doi: 10.1016/j.drugalcdep.2012.05.034

51. Cha HJ, Seong Y-H, Song M-J, Jeong H-S, Shin J, Yun J, et al. Neurotoxicity of synthetic cannabinoids JWH-081 and JWH-210. Biol Ther. (2015) 23:597–603. doi: 10.4602/biolthermol.2015.007

52. Wiley JL, Marusich JA, Martin BR, Huffman JW. 1-phenyl-3- phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice. Drug Alcohol Depend. (2012) 123:148–53. doi: 10.1016/j.drugalcdep.2011.11.001

53. Wiley JL, Marusich JA, Lefever TW, Antozanzo KR, Wallgren MT, Cortes RA, et al. AB-CHMINACA, AB-PINACA, and FUBIMINA: affinity and potency of novel synthetic cannabinoids in producing A 9 -tetrahydrocannabinol-like effects in mice. J Pharmacol Exp Ther. (2015) 354:328–39. doi: 10.1124/jpet.115.225326

54. Cannizzaro A, Malta G, Argo A, Brancato A, Roda G, Casagni E, et al. Behavioral and pharmacological characterization of a novel cannabinominotic adamantane-derived indole, APICA, and considerations on the possible misuse as a psychotropic spice abuse, in C57bl/6j mice. Forensic Sci Int. (2016) 265:6–12. doi: 10.1016/j.forsciint.2015.12.035

55. Gatch MB, Forster MJ. Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids. Neurotoxicology. (2019) 70:72–9. doi: 10.1016/j.neurotox.2018.11.004

56. Lemos NP. Driving under the influence of synthetic cannabinoid receptor agonist XLR-11. J Forensic Sci. (2014) 59:1679–83. doi: 10.1111/1556-4029.12550
57. Yeake1 JK, Logan BK. Blood synthetic cannabinoid concentrations in cases of suspected impaired driving. J Anal Toxicol. (2013) 37:547–51. doi: 10.1093/jat/bkt065
58. Peterson BL, Couper FJ. Concentrations of AB-CHMINACA and AB-PINACA and driving behavior in suspected impaired driving cases. J Anal Toxicol. (2015) 39:642–7. doi: 10.1093/jat/bkv091
59. Fels H, Herzog J, Skopp G, Holzer A, Paul LD, Graw M, et al. Retrospective analysis of new psychoactive substances in blood samples of German drivers suspected of driving under the influence of drugs. Drug Test Anal. (2020) 12:1470–6. doi: 10.1002/dta.2897
60. Adamowicz P, Lechowicz W. The influence of synthetic cannabinoid UR-144 on human psychomotor performance—a case report demonstrating road traffic risks. Traffic Inj Prev. (2015) 16:754–9. doi: 10.1080/15389588.2015.1018990
61. Musshoff F, Madea B, Kernbach-Wighton G, Bicker W, Kreisel S, Hatter M, et al. Driving under the influence of synthetic cannabinoids (“Spice”): a case series. Int J Legal Med. (2014) 128:59–64. doi: 10.1007/s00414-013-0864-1
62. Louis A, Peterson BL, Couper FJ. XLR-11 and UR-144 in Washington State and State of Alaska driving cases. J Anal Toxicol. (2014) 38:363–8. doi: 10.1093/jat/bku067
63. Tuv SS, Krabseth H, Karinen R, Olsen KM, Øiestad EL, Vindenes V. Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period. Accid Anal Prev. (2014) 66:104–8. doi: 10.1016/jxacca.2013.09.009
64. Kaneko S. Motor vehicle collisions caused by the ‘super-strength’ synthetic cannabinoids, MAM-2201, 5F-PB-22, 5F-AB-PINACA, 5F-AMB and 5F-ADB in Japan experienced from 2012 to 2014. Forensic Sci. (2017) 35:244–51. doi: 10.1007/s11419-017-0369-6
65. Kleis J, Gerrerotto T, Halter S, Héroux V, Schwarz C, et al. The synthetic cannabinoid 5F-MDMB-PICA: a case series. Forensic Sci. Int. (2020) 314:109104. doi: 10.1016/j.forsciint.2020.109104
66. Jaenicke NJ, Pogoda W, Paulke A, Wunder C, Toennes SW. Retrospective analysis of synthetic cannabinoids in serum samples—epidemiology and consumption patterns. Forensic Sci. Int. (2014) 242:81–7. doi: 10.1016/j.forsciint.2014.06.010
67. McCain KR, Jones JO, Chilbert KT, Patton AL, James LP, Moran JH. Impaired driving associated with the synthetic cannabinoid 5F-ADB. J Forensic Sci Criminal. (2018) 6:105. doi: 10.1007/s12118-018-9904-6.105
68. Kraemer M, Fels H, Dame T, Musshoff F, Halter S, Mogler L, et al. Mono-polytoxicity with 5F-ADB: a case series. Forensic Sci. Int. (2019) 301:249–237. doi: 10.1016/j.forsciint.2019.05.017
69. Centela C, Giorgetti A, Zaami S, Giorgetti R. Effects of GHB on psychomotor and driving performance. Curr Drug Metab. (2018) 19:1065–72. doi: 10.2174/138920021966618012413802
70. Reagen-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. (2008) 22:659–61. doi: 10.1096/faseb.2007.95741LSF
71. Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, et al. Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB- PINACA, 5F-ADB-PINACA, ADBHICA, and 5F-ADBICA. ACS Chem Neurosci. (2015) 6:1546–59. doi: 10.1021/acscchemneuro.5b00112
72. Antonides LH, Cannaert A, Norman C, Vives L, Harrison A, Costello A, et al. Enantiomeric, chiral, and biological activity of four indazole-3-carboxamide-type synthetic cannabinoid receptor agonists and their detection in seized drug samples. Front Chem. (2019) 7:321. doi: 10.3389/fchem.2019.00321
73. Giorgetti A, Barone R, Pelletti G, Garagnani M, Pascali J, Haschimi B, et al. Development and validation of a rapid LC-MS/MS method for the detection of 182 novel psychoactive substances in whole blood. Drug Test Anal. (2022) 14:202–23. doi: 10.1002/dta.3170
74. Kim NS, Lim NY, Choi HS, Lee JH, Kim H, Baek SY. Application of a simultaneous screening method for the detection of new psychoactive substances in various matrix samples using liquid chromatography/electrospray ionization tandem mass spectrometry and liquid chromatography/quadrupole time-of-flight mass. Rapid Commun Mass Spectrom. (2021) 35:e9067. doi: 10.1002/rcm.9067
75. Ong RS, Kappatos DC, Russell SGG, Poulsen HA, Banister SD, Gerona RR, et al. Simultaneous analysis of 29 synthetic cannabinoids and metabolites, amphetamines, and cannabinoids in human whole blood by liquid chromatography-tandem mass spectrometry - A New Zealand perspective of use in 2018. Drug Test Anal. (2020) 12:195–214. doi: 10.1002/dta.2697
76. Krotulski AJ, Mohr ALA, Logan BK. Emerging synthetic cannabinoids: development and validation of a novel liquid chromatography-quadrupole time-of-flight mass spectrometry assay for real-time detection. J Anal Toxicol. (2020) 44:207–17. doi: 10.1093/jat/bku084
77. Vaiano F, Busardo FP, Palumbo D, Kyriakou C, Fioravanti A, Catalani V, et al. A novel screening method for 64 new psychoactive substances and 5 amphetamines in blood by LC-MS/MS and application to real cases. J Pharm Biomed Anal. (2016) 129:441–9. doi: 10.1016/j.jpba.2016.07.019
78. Haschimi B, Mogler L, Halter S, Giorgetti A, Schwarze B, Westphal F, et al. Detection of the recently emerged synthetic cannabinoid 4F-MDMB-PINACA in “legal high” products and human urine specimens. Drug Test Anal. (2019) 11:1377–86. doi: 10.1002/dta.2666
79. Fagiola M, Hahn T, Avella J. Screening of novel psychoactive substances in postmortem matrices by liquid chromatography-tandem mass spectrometry (LC-MS-MS). J Anal Toxicol. (2018) 42:562–9. doi: 10.1093/jat/bky030
80. Kronstrand R, Mann M, Andersson M, Eklund A. Toxicological findings of synthetic cannabinoids in recreational users. J Anal Toxicol. (2013) 37:334–41. doi: 10.1093/jat/bkt068
81. Busardo FP, Pichini S, Pellegrini M, Montana A, Lo Faro AF, Zaami S, et al. Correlation between blood and oral fluid concentrations of synthetic cannabinoids and cognitive impairment in driving under the influence of drugs. Curr Neuropharmacol. (2016) 14:86–96. doi: 10.2174/1570159X15666170828162057
82. United Kingdom Government. Circular 009/2019 Third Generation Synthetic Cannabinoids Update. (2019). Available online at: https:// www.gov.uk/government/publications/circular-0092019-third-generation-synthetic-cannabinoids-update/circular-0092019-third-generation-synthetic-cannabinoids-update
83. Chase PB, Hawkings J, Mosier J, Jimenez E, Bossen K, Logan BK, et al. Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs. Clin Toxicol. (2016) 54:14–9. doi: 10.1089/cln.2015.110769
84. Adamowicz P, Gieron J, Gil D, Lechowicz W, Skulsk A, Tokarczyk B. The prevalence of new psychoactive substances in biological material - a three-year review of casework in Poland. Drug Test Anal. (2016) 8:64–71. doi: 10.1002/dta.1924
85. Funada M, Takebayashi-Ohsawa M, Tominaga K. Synthetic cannabinoids enhanced ethanol-induced motor impairments through reduction of central glutamate neurotransmission. Toxicol App Pharmacol. (2020) 408:115283. doi: 10.1016/j.taap.2020.115283